Does Humana Cover Metformin? Formulary Tiers, Prior Auth, and Appeal Steps

Humana Formulary Placement for Metformin

Generic metformin hydrochloride sits on the lowest-cost tier of nearly every Humana formulary. For most Humana commercial PPO, HMO, and Medicare Advantage (MA) plans, immediate-release metformin (500 mg, 850 mg, 1,000 mg) lands on Tier 1 (preferred generic). Extended-release metformin (metformin ER) also appears on Tier 1 or Tier 2, depending on the specific plan document.

Brand-name Glucophage and Glucophage XR are placed on Tier 3 (non-preferred brand) when listed at all. The price difference is substantial. A 30-day supply of generic metformin 1,000 mg twice daily costs most Humana members between $0 and $15, while Glucophage XR can carry a $40 to $75 copay on the same plan.

The American Diabetes Association (ADA) Standards of Care recommend metformin as first-line pharmacotherapy for type 2 diabetes. That guideline status is exactly why insurers, Humana included, keep it on preferred tiers with minimal access barriers. UKPDS 34 (N=1,704) demonstrated that metformin reduced diabetes-related mortality by 42% compared with conventional therapy in overweight patients with newly diagnosed type 2 diabetes (Lancet 1998). That landmark evidence has anchored formulary committees' decisions for more than two decades.

Humana updates its formularies quarterly. The specific tier for your plan can be verified by logging in at humana.com or calling the member services number on the back of your card. Formulary documents are also searchable by drug name in the Humana Drug List Tool.

Prior Authorization Rules on Humana Plans

For type 2 diabetes, Humana does not require prior authorization (PA) for generic metformin on the vast majority of its plans. The drug's Tier 1 status and first-line guideline positioning mean the pharmacy benefit manager (PBM) processing Humana claims will approve it at the point of sale without additional paperwork.

Exceptions exist. PA may be triggered when:

• The prescribed dose exceeds 2,550 mg per day (the FDA-labeled maximum for immediate-release) or 2,000 mg per day (the labeled maximum for extended-release), as noted on the metformin prescribing information.
• The prescriber writes for brand-name Glucophage or Glucophage XR instead of generic. Humana's formulary management protocols include a generic-first step edit, meaning the pharmacy system will reject the brand claim and prompt a switch to generic unless PA is obtained.
• The prescription is written for an off-label indication such as weight management, polycystic ovary syndrome (PCOS), or prediabetes reversal.

PA difficulty for off-label metformin on Humana MA plans is moderate to high. CMS rules restrict Medicare Part D formularies from covering drugs for indications not in their approved labeling or in accepted compendia. Because metformin's FDA-approved indication is type 2 diabetes, a Medicare Advantage enrollee seeking metformin solely for weight loss may receive an outright denial rather than a PA request.

The ADA notes that metformin can be considered for prediabetes prevention, citing the Diabetes Prevention Program (DPP), which showed metformin 850 mg twice daily reduced progression to type 2 diabetes by 31% over 2.8 years versus placebo (N=3,234) (Knowler et al., NEJM 2002). Some Humana commercial plans do cover metformin for prediabetes with a supporting A1C or fasting glucose lab result, but coverage is plan-specific.

Metformin for Weight Loss: Will Humana Pay?

Humana commercial plans occasionally cover metformin for weight management when prescribed alongside a documented diagnosis of insulin resistance, metabolic syndrome, or prediabetes. The claim is more likely to process if the prescriber codes the encounter with an ICD-10 tied to a metabolic condition (E11.x for type 2 diabetes, R73.03 for prediabetes, E88.81 for metabolic syndrome) rather than a pure obesity code (E66.x).

Medicare Advantage is different. CMS does not classify metformin as an anti-obesity medication, and Part D formularies generally will not cover a drug prescribed exclusively for weight loss. The Endocrine Society's 2015 Clinical Practice Guideline on pharmacological management of obesity acknowledges that metformin produces modest weight reduction (typically 2 to 3 kg), but it is not FDA-approved for that purpose.

Dr. Irl Hirsch, professor of medicine at the University of Washington, has stated: "Metformin's weight effect is real but modest. Expecting it to replace dedicated anti-obesity agents is a clinical miscalculation."

For context, UKPDS 34 reported that patients assigned to metformin gained less weight than those on sulfonylureas or insulin, with a mean difference of approximately 3 to 4 kg over the study period (UKPDS 34, Lancet 1998). That is meaningful for metabolic health. It is not comparable to the 14.9% mean body weight loss seen with semaglutide 2.4 mg in STEP-1 (N=1,961) (Wilding et al., NEJM 2021).

If your prescriber believes metformin is clinically necessary for weight-related metabolic dysfunction, submit a PA request with:

1. Recent A1C and fasting glucose results
2. Documentation of BMI and comorbidities
3. A letter of medical necessity citing the DPP trial data and ADA prediabetes guidance

Step Therapy Requirements

Humana does not impose step therapy on metformin for type 2 diabetes. Metformin is the step-one agent. Other diabetes medications, including SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors, frequently require documentation that metformin was tried first (or is contraindicated) before Humana will approve them.

The situation reverses for off-label use. If a Humana member requests coverage for metformin for PCOS, the plan may require evidence that lifestyle modifications (diet, exercise) were attempted for a defined period before approving the prescription. This is not a formal step-therapy edit in the pharmacy system; it is a medical-necessity criterion embedded in the PA review process.

The AACE/ACE Comprehensive Type 2 Diabetes Management Algorithm positions metformin as the foundational oral agent, with escalation to dual or triple therapy when A1C remains above target after 3 months. Humana's step-therapy logic for second-line agents mirrors this algorithm closely.

How to Appeal a Humana Metformin Denial

A denial typically arrives as an Explanation of Benefits (EOB) letter or a pharmacy rejection code at the point of sale. The appeal process has defined timelines you should know.

Step 1: Standard internal appeal. File within 180 days of the denial. Include a letter from your prescriber explaining the clinical rationale, relevant lab work, and guideline citations. Humana must respond within 30 calendar days for a standard appeal or 72 hours for an expedited appeal involving urgent medical need.

Step 2: External review (commercial plans). If the internal appeal is denied, you can request an independent external review through your state's insurance department. The external reviewer is not affiliated with Humana.

Step 3: Medicare-specific pathway (MA plans). For Medicare Advantage denials, the appeal escalates to an Independent Review Entity (IRE). If that fails, the case moves to the Office of Medicare Hearings and Appeals (OMHA). The MAXIMUS Federal Services contractor administers IRE reviews for Part D drug denials. The CMS Medicare Appeals Process page outlines each level.

Dr. Jeffrey Mechanick, past president of the American Association of Clinical Endocrinologists, has noted in clinical commentary: "When a formulary denial contradicts guideline-based prescribing, a well-documented appeal citing specific trial evidence succeeds more often than clinicians expect."

Tips for a successful appeal:

• Reference the ADA Standards of Care and UKPDS 34 by name in the appeal letter
• Attach lab values showing the metabolic indication (A1C, fasting glucose, HOMA-IR if available)
• Include a pharmacy printout showing the specific rejection code
• Ask your prescriber's office to submit the appeal, as physician-initiated appeals carry more weight than patient-initiated ones

Cost Comparison: Humana vs. Cash Pay

Generic metformin is one of the cheapest prescription drugs in the United States. The cash-pay price averages roughly $8 per month at large chain pharmacies, sometimes dropping below $4 with discount programs like GoodRx, RxSaver, or Mark Cuban's Cost Plus Drugs. Humana copays for Tier 1 generics range from $0 (many MA plans with $0 generic copay benefits) to $15.

This means the out-of-pocket difference between using Humana and paying cash is often negligible. If your Humana plan has a $10 copay for Tier 1 drugs, paying $8 cash may actually be cheaper. Pharmacists can run both the insurance claim and a cash-price check at the counter.

For brand-name Glucophage XR (approximately $40/month list price), the math changes. Humana's Tier 3 copay might be $40 to $75, making generic substitution the clear financial choice. The FDA considers generic metformin therapeutically equivalent to Glucophage under its Orange Book AB-rated classification, meaning pharmacists can substitute freely unless the prescriber writes "dispense as written."

A 2020 analysis published in Diabetes Care found that among Medicare Part D beneficiaries, out-of-pocket spending on metformin decreased by 37% between 2007 and 2018, driven almost entirely by generic competition and $0-copay benefit designs (Lipska et al., Diabetes Care 2020).

Manufacturer Savings Cards and Humana

Manufacturer copay cards (sometimes called savings cards or coupons) are issued by brand-name drug makers to reduce patient cost-sharing. Because generic metformin dominates the market and carries minimal copays, manufacturer savings cards for metformin are essentially nonexistent. Bristol-Myers Squibb, the original manufacturer of Glucophage, discontinued its copay assistance program years ago.

If your prescriber insists on brand Glucophage XR for a clinical reason (such as GI tolerability with the specific extended-release matrix), and your Humana copay is high, your options include:

• Asking the pharmacy to check if an authorized generic of Glucophage XR is available at a lower tier
• Using a GoodRx or similar discount coupon instead of the insurance benefit
• Requesting a formulary exception through Humana to move the brand to a lower tier

One important rule: Medicare Advantage and Part D plans prohibit the use of manufacturer copay cards. This is a CMS regulation, not a Humana-specific policy. If you are on a Humana MA plan, manufacturer coupons cannot be applied to your Part D prescriptions under federal law (CMS guidance on manufacturer coupons).

Special Populations and Coverage Nuances

Humana covers metformin for pregnant patients only when the prescriber documents gestational diabetes (ICD-10 O24.x) and the clinical rationale for metformin over insulin. The ACOG Practice Bulletin on Gestational Diabetes notes that while insulin remains the preferred pharmacotherapy, metformin is a reasonable alternative when insulin is refused or impractical.

For pediatric patients (age 10 and older), metformin is FDA-approved for type 2 diabetes. Humana covers it without PA for this indication. Off-label pediatric use for obesity or insulin resistance may trigger a PA review, and coverage varies by plan.

Renal dosing adjustments also affect coverage indirectly. The FDA updated metformin labeling in 2016 to allow use in patients with eGFR 30 to 45 mL/min/1.73 m² at a reduced dose, expanding access for patients with moderate chronic kidney disease (FDA Drug Safety Communication, 2016). Humana formulary systems reflect this updated labeling, so claims for metformin in patients with moderate CKD should process without issue if the dose is within labeled parameters.